Trial Profile
A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
- Focus Adverse reactions
- Sponsors Novartis
- 12 May 2016 Results published in the Vaccine
- 28 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 13 May 2014 According to the ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.